A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the progression-free survival (PFS) of
participants with previously untreated metastatic malignant melanoma when treated with
IMC-1121B (ramucirumab) alone or in combination with dacarbazine.